Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $34.39 and last traded at $34.20, with a volume of 520210 shares trading hands. The stock had previously closed at $32.87. Wall Street Analyst Weigh In A number of […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 28.16% from the stock’s current […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 28.16% from the stock’s previous close. A […]
Verity Asset Management Inc. purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 7,211 shares of the biotechnology company’s stock, valued at approximately $234,000. A number of other institutional investors also recently bought and sold shares of CORT. FNY […]
StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a report published on Friday morning. Several other brokerages have also weighed in on CORT. Truist Financial increased their price objective on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a buy […]